Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

iwCLL 2019 | Entospletinib in combination with obinutuzumab in R/R CLL

Adam Kittai • 21 Sep 2019
iwCLL 2019
Chronic Lymphocytic Leukemia Leukemia Entospletinib Obinutuzumab

Adam Kittai, MD, Ohio State University, Columbus, OH, gave an overview of the phase I/II study of entospletinib in combination with obinutuzumab in patients with R/R chronic lymphocytic leukemia (CLL). This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

More from Adam Kittai

The uptake of targeted agents by race/ethnicity in patients receiving first-line treatment for CLL 3:54
The uptake of targeted agents by race/ethnicity in patients receiving first-line treatment for CLL
Adam Kittai • 12 Jun 2025
Recent developments in the treatment of Richter’s transformation 1:58
Recent developments in the treatment of Richter’s transformation
Adam Kittai • 12 Jun 2025
The ERIC recommendations for Richter’s transformation: guidelines for management & trial design 2:18
The ERIC recommendations for Richter’s transformation: guidelines for management & trial design
Adam Kittai • 12 Jun 2025
What’s on the horizon for patients with Richter’s transformation? 1:42
What’s on the horizon for patients with Richter’s transformation?
Adam Kittai • 10 Dec 2023

Related Videos

MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR 7:15
MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR
Talha Munir • 16 Dec 2025
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax 2:14
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax
Jorge Cortes • 7 Dec 2025
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML 2:22
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML
Jorge Cortes • 7 Dec 2025
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML 5:08
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML
Elisabetta Abruzzese • 5 Dec 2025
The content of VJHemOnc is intended for healthcare professionals